共 50 条
Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients
被引:84
|作者:
Cautela, Jennifer
[1
]
Tartiere, Jean-Michel
[2
]
Cohen-Solal, Alain
[3
]
Bellemain-Appaix, Anne
[4
]
Theron, Alexis
[5
]
Tibi, Thierry
[6
]
Januzzi, James L., Jr.
[7
]
Roubille, Francois
[8
]
Girerd, Nicolas
[9
,10
,11
]
机构:
[1] Aix Marseille I Univ, Hop Nord, Mediterranean Univ Cardiooncol Ctr MED ICO Ctr, Dept Cardiol,Heart Failure & Valvular Heart Dis U, Marseille, France
[2] Hop St Musse, Cardiol Dept, Toulon, France
[3] Paris Univ, Hop Lariboisiere, AP HP, CUMR S 942,MASCOT,Cardiol Dept, Paris, France
[4] Ctr Hosp Antibes Juan Pins, Cardiol Dept, Antibes, France
[5] Hop La Timone, Cardiothorac Surg Dept, Marseille, France
[6] Ctr Hosp Cannes, Cardiol Dept, Cannes, France
[7] Harvard Med Sch, Massachusetts Gen Hosp, Baim Inst Clin Res, Cardiol Div, Boston, MA 02115 USA
[8] Univ Montpellier, CHU Montpellier, CNRS, PhyMedExp,INSERM,Cardiol Dept, Montpellier, France
[9] Univ Lorraine, Vandoeuvre Nancy France Grp Choc, Ctr Invest Clin Plurithemat 1433,INSERM U1116, Inst Lorrain Coeur & Vaisseaux,Fac Med, Vandoeuvre Les Nancy, France
[10] F CRIN INI CRCT Cardiovasc & Renal Clin Trialists, Nancy, France
[11] CHRU Nancy, Inst Lorrain Coeur & Vaisseaux, Cardiol Dept, Nancy, France
关键词:
Hypotension;
Heart failure;
Beta-blocker;
Angiotensin-converting enzyme inhibitor;
Angiotensin receptor blocker;
Angiotensin receptor-neprilysin inhibitor;
Mineralocorticoid receptor antagonist;
Diuretics;
LEFT-VENTRICULAR DYSFUNCTION;
PULSE PRESSURE;
SACUBITRIL/VALSARTAN LCZ696;
PROGNOSTIC VALUE;
DOUBLE-BLIND;
SURVIVAL;
MORTALITY;
BLOCKER;
ENALAPRIL;
CARVEDILOL;
D O I:
10.1002/ejhf.1835
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Low blood pressure is common in patients with heart failure and reduced ejection fraction (HFrEF). While spontaneous hypotension predicts risk in HFrEF, there is only limited evidence regarding the relationship between hypotension observed during heart failure (HF) drug titration and outcome. Nevertheless, hypotension (especially orthostatic hypotension) is an important factor limiting the titration of HFrEF treatments in routine practice. In patients with signs of shock and/or severe congestion, hospitalization is advised. However, in the very frequent cases of non-severe and asymptomatic hypotension observed while taking drugs with a class I indication in HFrEF, European and US guidelines recommend maintaining the same drug dosage. In instances of symptomatic or severe persistent hypotension (systolic blood pressure < 90 mmHg), it is recommended to first decrease blood pressure reducing drugs not indicated in HFrEF as well as the loop diuretic dose in the absence of associated signs of congestion. Unless the management of hypotension appears urgent, a HF specialist should then be sought rather than stopping or decreasing drugs with a class I indication in HFrEF. If symptoms or severe hypotension persist, no recommendations exist. Our HF group reviewed available evidence and proposes certain steps to follow in such situations in order to improve the pharmacological management of these patients.
引用
收藏
页码:1357 / 1365
页数:9
相关论文